Plurilock Announces Amendment to Terms of Convertible Debentures and Warrant Inducement Program and Closing of Debt Settlement
Plurilock Announces CA$900,000 Sale to Canadian Federal Government Agency and Engagement of Investor Relations Service Providers
Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹?¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
